NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: BioCorRx Board Leadership Transition and Company Overview
TL;DR
BioCorRx appoints experienced Louis Lucido as Board Chair, ensuring leadership continuity that could strengthen governance and strategic execution for competitive advantage.
BioCorRx's planned leadership transition involves Louis Lucido becoming Board Chair while Kent Emry remains as independent director, maintaining governance continuity through established processes.
BioCorRx's leadership continuity supports its mission to develop innovative treatments for substance abuse and obesity, potentially improving lives and public health outcomes.
BioCorRx's new Board Chair Louis Lucido brings extensive experience while the company develops implantable naltrexone pellets and FDA-approved opioid withdrawal medication.
Found this article helpful?
Share it with your network and spread the knowledge!
BioCorRx Inc. announced that Louis Lucido has been appointed as Chair of the Company's Board of Directors, effective January 1, 2026, as part of a planned leadership transition.
Louis Lucido has been a member of BioCorRx's Board since 2019, served as President since 2024, and brings extensive board leadership experience including serving as Chair for other organizations.
Kent Emry, who served on BioCorRx's Board since 2013, will continue to serve as an independent director, ensuring continuity of leadership and governance.
The appointment of Louis Lucido as Board Chair became effective on January 1, 2026.
BioCorRx Inc. is an addiction treatment solutions company offering programs for substance use disorders and weight loss, including the Beat Addiction Recovery program and UnCraveRx® Weight Loss Program.
BioCorRx offers the Beat Addiction Recovery program for substance use disorders and the UnCraveRx® Weight Loss Program, both incorporating medication assistance and behavioral support components.
Through BioCorRx Pharmaceuticals Inc., the company focuses on pharmaceutical commercialization including LUCEMYRA® (lofexidine) for opioid withdrawal and development of BICX104, an investigational implantable naltrexone pellet program.
For more information on UnCraveRx®, visit www.uncraverx.com, and for information on BioCorRx and its subsidiary pipeline, visit www.BioCorRx.com.
This transition ensures continuity while positioning Mr. Lucido, with his deep understanding of the company and extensive board leadership experience, to lead BioCorRx as it advances its strategic objectives in addiction treatment.
Research reported in the publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number U01DA059994.
Curated from NewMediaWire
